Cagrilintide and Amylin-Pathway Research: The Second Satiety Axis

Incretins dominated the last decade of metabolic research; the amylin pathway may define the next. Cagrilintide, a long-acting amylin analogue, is the compound carrying that hypothesis.

The amylin system

Amylin is co-secreted with insulin from pancreatic beta cells, acting on receptors formed by the calcitonin receptor plus RAMP proteins — a completely separate axis from GLP-1/GIP signalling. Two independent satiety pathways means combination potential, which is exactly where the field went.

Cagrilintide's design

A 37-amino-acid analogue with a fatty-diacid albumin-binding side chain (the same longevity strategy as semaglutide), engineered to activate amylin and calcitonin receptors with a half-life supporting weekly-scale dosing in clinical work.

Why researchers want it now

Phase-2 combination data with semaglutide (the pairing known as CagriSema) made it one of the most-watched molecules in metabolic science. Receptor researchers study it for RAMP-complex pharmacology; signalling labs for the incretin-amylin interaction question. Our CagriSema article covers the combination logic.

For laboratories and peptide businesses buying at volume, wholesale trade packs — sourced and tested in Australia — are available through our wholesale and white-label page.

All compounds discussed are for in-vitro laboratory research only and are not for human or veterinary use.